On 29 September 2021, Tibet Duo Rui Pharmaceutical Co., Ltd. (301075. SZ, “Tibet Duorui”) was successfully listed on the ChiNext Market of Shenzhen Stock Exchange.  Grandall shanghai acted as the issuer's legal counsel.

Established in 2016, Tibet Dorui mainly engages in the research, development, production and sale of chemical pharmaceutical preparations.  Aimed at becoming a leading company in the special segment in China, the company endeavors to improve patients' medication experience and enhance product competitiveness.

Grandall Shanghai has been retained as the issuer's legal counsel with LI Qiang (managing partner and director of Grandall Shanghai), LI Chen (partner of Grandall Shanghai), ZHENG Yijun and GE Tao (associates of Grandall Shanghai), HUANG Qian (partner of Grandall Wuhan), YANG Hui and ZHOU Fengmei (associates of Grandall Wuhan), and WANG Cong (associate of Grandall Urumqi) providing comprehensive and professional legal services for the project.